StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
138
This month
3
This year
18
Publishing Date
2024 - 02 - 15
2
2024 - 01 - 22
2
2023 - 12 - 20
2
2023 - 10 - 22
3
2023 - 10 - 21
2
2022 - 10 - 31
2
2022 - 08 - 31
1
2022 - 08 - 23
1
2022 - 08 - 22
1
2022 - 08 - 03
1
2022 - 07 - 26
1
2022 - 07 - 12
1
2022 - 07 - 05
1
2022 - 06 - 23
1
2022 - 06 - 17
1
2022 - 05 - 20
1
2022 - 05 - 18
1
2022 - 04 - 28
1
2022 - 04 - 06
1
2022 - 03 - 30
1
2022 - 03 - 03
1
2022 - 02 - 18
2
2022 - 02 - 14
2
2022 - 01 - 31
1
2022 - 01 - 20
1
2021 - 12 - 13
2
2021 - 12 - 09
1
2021 - 12 - 03
2
2021 - 11 - 25
1
2021 - 10 - 25
1
2021 - 10 - 15
2
2021 - 09 - 20
1
2021 - 09 - 19
2
2021 - 08 - 24
1
2021 - 08 - 19
1
2021 - 08 - 18
1
2021 - 08 - 10
1
2021 - 08 - 06
1
2021 - 08 - 05
1
2021 - 08 - 04
1
2021 - 07 - 29
1
2021 - 07 - 26
1
2021 - 07 - 22
1
2021 - 07 - 19
1
2021 - 06 - 22
1
2021 - 06 - 17
2
2021 - 06 - 08
1
2021 - 05 - 25
1
2021 - 05 - 24
2
2021 - 05 - 21
3
2021 - 05 - 19
1
2021 - 05 - 11
1
2021 - 04 - 23
1
2021 - 04 - 21
1
2021 - 04 - 09
1
2021 - 01 - 29
1
2021 - 01 - 12
1
2020 - 12 - 15
1
2020 - 12 - 04
2
2020 - 12 - 03
1
Sector
Communications
1
Consumer non-durables
1
Finance
2
Health services
3
Health technology
138
Manufacturing
4
N/a
1
Tags
Agreement
50
Alliances
52
Antibody
44
Approval
93
Biopharma
173
Biotech-beach
46
Biotechnology
118
Cancer
138
Care
64
Ceo
58
Clinical-trials-phase-ii
54
Clinical-trials-phase-iii
52
Collaboration
58
Commercialization
50
Conference
64
Covid
298
Covid-19
227
Device
76
Disease
107
Drug
224
Earnings
52
Europe
51
Events
49
Expected
59
Fda
225
Fda-approvals
59
Financial
72
Global
422
Growing
64
Growth
300
Health
98
Layoffs
81
License
45
Market
762
Medical
63
Merge
54
Money
93
N/a
2883
News
163
People
229
Pharm-country
70
Pharma
104
Pharmaceutical
97
Positive
46
Product-news
57
Reach
63
Regulatory
57
Report
345
Research
318
Results
217
Sales
53
Study
67
Technology
45
Therapeutics
186
Therapy
103
Treatment
195
Trial
99
Update
41
Vaccine
327
Year
54
Entities
Abbott laboratories
9
Abbvie inc.
4
Adaptimmune therapeutics plc
1
Amgen inc.
8
Angiodynamics, inc.
1
Anixa biosciences, inc.
1
Astellas pharma inc
1
Astrazeneca plc
8
Baxter international inc.
1
Becton, dickinson and company
2
Bio-rad laboratories, inc.
1
Biocept, inc.
1
Biogen inc.
1
Blueprint medicines corporation
1
Boston scientific corporation
3
Bristol-myers squibb company
11
Clovis oncology, inc.
1
Conmed corporation
1
Edgewell personal care
1
Eli lilly and company
11
Essa pharma inc.
2
Exact sciences corporation
1
Exelixis, inc.
1
First bank
2
Genmab a/s
5
Gilead sciences, inc.
1
Glaxosmithkline plc
6
Illumina, inc.
1
Immix biopharma, inc.
1
Intuitive surgical, inc.
1
Jazz pharmaceuticals plc
1
Johnson & johnson
138
Koninklijke philips nv
1
Laboratory corporation of america holdings
1
Medtronic plc
1
Nanobiotix - adr
2
Novartis ag
12
Orange
1
Perrigo company
6
Pfizer, inc.
4
Qiagen n.v.
1
Quest diagnostics incorporated
1
Sanofi
21
Seagen inc.
1
Smith & nephew plc
1
Stryker corporation
1
Takeda pharmaceutical company limited
4
Teleflex incorporated
1
Terumo corp
1
Teva pharmaceutical industries ltd
1
Thermo fisher scientific inc
1
Ucb s.a.
1
Unilever plc
1
Veracyte, inc.
1
Vertex pharmaceuticals incorporated
1
Zimmer biomet holdings, inc.
1
Symbols
A
27
ABBV
53
ABT
48
ALPMF
49
ALPMY
49
AMGN
91
ANIX
48
ARAY
26
AVEO
24
AZN
144
AZNCF
74
BCTX
50
BDX
26
BGNE
58
BIOC
31
BMY
107
BPMC
27
CLVS
33
CSTL
28
EXAS
56
EXEL
43
FNCTF
138
GH
53
GILD
59
GLAXF
46
GNPX
26
GSK
54
GTHX
27
HOLX
32
HOTH
29
IBRX
29
ILMN
68
IMGN
25
IMMP
34
INCY
57
JAGX
36
JNJ
138
KPTI
27
LLY
139
LTRN
24
MRK
75
MRTX
32
MYGN
50
NTRA
38
NVCR
30
NVS
106
NVSEF
91
NVTA
25
ONCY
41
PDSB
34
PFE
66
QGEN
31
REGN
42
SGEN
55
SNY
215
SNYNF
165
TAK
34
TMO
51
VCYT
45
VSTM
25
Exchanges
Nasdaq
50
Nyse
138
Crawled Date
2024 - 02 - 15
2
2024 - 01 - 22
2
2023 - 12 - 20
2
2023 - 10 - 22
3
2023 - 10 - 21
2
2022 - 10 - 31
2
2022 - 08 - 31
1
2022 - 08 - 23
1
2022 - 08 - 22
1
2022 - 08 - 03
1
2022 - 07 - 26
1
2022 - 07 - 12
1
2022 - 07 - 05
1
2022 - 06 - 23
1
2022 - 06 - 17
1
2022 - 05 - 20
1
2022 - 05 - 18
1
2022 - 04 - 28
1
2022 - 04 - 06
1
2022 - 03 - 30
1
2022 - 03 - 03
1
2022 - 02 - 18
2
2022 - 02 - 14
2
2022 - 01 - 31
1
2022 - 01 - 20
1
2021 - 12 - 13
2
2021 - 12 - 09
1
2021 - 12 - 03
2
2021 - 11 - 25
1
2021 - 10 - 25
1
2021 - 10 - 15
2
2021 - 09 - 20
1
2021 - 09 - 19
2
2021 - 08 - 24
1
2021 - 08 - 19
1
2021 - 08 - 18
1
2021 - 08 - 10
1
2021 - 08 - 06
1
2021 - 08 - 05
1
2021 - 08 - 04
1
2021 - 07 - 29
1
2021 - 07 - 26
1
2021 - 07 - 22
1
2021 - 07 - 19
1
2021 - 06 - 22
1
2021 - 06 - 17
2
2021 - 06 - 08
1
2021 - 05 - 25
1
2021 - 05 - 24
2
2021 - 05 - 21
3
2021 - 05 - 19
1
2021 - 05 - 11
1
2021 - 04 - 23
1
2021 - 04 - 21
1
2021 - 04 - 09
1
2021 - 01 - 29
1
2021 - 01 - 13
1
2020 - 12 - 15
1
2020 - 12 - 04
2
2020 - 12 - 03
1
Crawled Time
00:00
2
00:11
1
00:20
1
01:00
2
02:00
1
04:00
2
04:08
1
04:20
1
07:00
1
08:00
5
08:20
4
09:00
3
10:00
2
11:00
6
11:01
1
12:00
4
12:20
1
12:30
1
13:00
8
13:15
1
13:20
2
13:30
1
14:00
6
14:15
1
14:20
3
14:30
3
15:00
6
15:15
2
15:20
1
15:30
3
16:00
5
16:20
4
17:00
9
18:00
5
19:00
5
20:00
9
20:20
2
21:00
8
22:00
11
23:00
4
Source
www.biospace.com
54
www.globenewswire.com
8
www.prnewswire.com
76
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Cancer
symbols :
JNJ
save search
American Lung Association and LUNGevity Foundation Announce $3 Million Research Partnership to Intercept Lung Cancer
Published:
2024-04-09
(Crawled : 11:00)
- biospace.com/
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-4.63%
|
O:
-0.3%
H:
0.0%
C:
0.0%
partnership
lung
association
million
cancer
research
foundation
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
Published:
2024-04-02
(Crawled : 20:00)
- globenewswire.com
NBTX
|
News
|
$5.35
-3.08%
-3.18%
43K
|
Manufacturing
|
-11.8%
|
O:
3.11%
H:
1.19%
C:
-2.54%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-8.22%
|
O:
0.02%
H:
0.0%
C:
0.0%
lung
cancer
treatment
Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy
Published:
2024-04-01
(Crawled : 11:00)
- prnewswire.com
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-8.46%
|
O:
-0.28%
H:
0.27%
C:
0.04%
cancer
therapy
RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson's ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer
Published:
2024-03-18
(Crawled : 12:00)
- prnewswire.com
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-8.52%
|
O:
0.2%
H:
0.08%
C:
-1.14%
rybrevant
lung
cancer
cell
care
World Cancer Immunotherapy Market Research 2023-2027: Curing Cancer is Generating Enormous New Opportunities - Outcome Potential, Technology Environment, Target Solutions
Published:
2024-03-16
(Crawled : 04:20)
- prnewswire.com
BIIB
|
$192.13
-1.55%
-1.57%
1.3M
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
Email alert
Add to watchlist
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
Email alert
Add to watchlist
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
Email alert
Add to watchlist
world
cancer
research
solutions
immunotherapy
technology
market
Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer
Published:
2024-03-14
(Crawled : 08:00)
- prnewswire.com
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-10.9%
|
O:
-1.04%
H:
0.0%
C:
0.0%
cancer
treat
series
cell
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published:
2024-03-01
(Crawled : 21:00)
- prnewswire.com
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
Email alert
Add to watchlist
rybrevant
fda
first
lung
approved
cancer
cell
treatment
therapy
Liquid Biopsy Market Set to Reach US$ 10.08 Billion by 2030 with Pioneering Breakthroughs in Cancer Detection and Management
Published:
2024-02-16
(Crawled : 19:00)
- prnewswire.com
TMO
|
News
|
$547.25
-1.32%
-0.02%
1.6M
|
Health Technology
|
Email alert
Add to watchlist
EXAS
|
$63.21
-1.02%
-1.03%
2.5M
|
Health Technology
|
Email alert
Add to watchlist
QGEN
|
$39.23
-0.23%
0.0%
800K
|
Health Technology
|
Email alert
Add to watchlist
QGEN
|
$39.23
-0.23%
0.0%
800K
|
Health Technology
|
Email alert
Add to watchlist
LH
M
|
$199.97
-0.97%
0.0%
680K
|
Health Services
|
Email alert
Add to watchlist
ILMN
|
$118.305
0.52%
0.52%
1.9M
|
Health Technology
|
Email alert
Add to watchlist
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
Email alert
Add to watchlist
management
reach
cancer
set
market
FDA Decisions: First Frontline Pancreatic Cancer Treatment Approved in More t...
Published:
2024-02-15
(Crawled : 17:00)
- biospace.com/
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
2.49%
|
O:
1.16%
H:
1.48%
C:
0.89%
PRGO
|
$30.04
0.27%
0.0%
780K
|
Health Technology
|
-4.82%
|
O:
0.67%
H:
2.06%
C:
1.86%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-7.36%
|
O:
-0.19%
H:
1.6%
C:
1.24%
ABT
|
News
|
$105.9
-3.03%
0.07%
12M
|
Health Technology
|
-3.69%
|
O:
0.41%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
0.99%
|
O:
1.86%
H:
0.0%
C:
0.0%
fda
first
approved
cancer
pancreatic
treatment
FDA Decisions: First Frontline Pancreatic Cancer Treatment Approved in More than a Decade
Published:
2024-02-15
(Crawled : 17:00)
- biospace.com/
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
2.49%
|
O:
1.16%
H:
1.48%
C:
0.89%
PRGO
|
$30.04
0.27%
0.0%
780K
|
Health Technology
|
-4.82%
|
O:
0.67%
H:
2.06%
C:
1.86%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-7.36%
|
O:
-0.19%
H:
1.6%
C:
1.24%
ABT
|
News
|
$105.9
-3.03%
0.07%
12M
|
Health Technology
|
-3.69%
|
O:
0.41%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
0.99%
|
O:
1.86%
H:
0.0%
C:
0.0%
fda
first
approved
cancer
pancreatic
treatment
Prevention and Treatment of Prostate Cancer: Global Market for Prostate Cancer Screening and Detection is Projected to Grow at a CAGR of 5.8% to Reach $19.8 billion by 2028
Published:
2024-02-09
(Crawled : 15:30)
- prnewswire.com
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-7.81%
|
O:
-0.68%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
0.04%
|
O:
1.11%
H:
0.0%
C:
0.0%
reach
cancer
treatment
global
market
Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published:
2024-02-06
(Crawled : 00:00)
- prnewswire.com
ALPMF
|
News
|
$9.594
43.47%
2.2K
|
Health Technology
|
-13.72%
|
O:
-1.53%
H:
0.0%
C:
0.0%
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
1.09%
|
O:
-0.37%
H:
0.0%
C:
0.0%
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
-8.98%
|
O:
0.41%
H:
0.0%
C:
0.0%
UCBJY
|
$63.31
-4.38%
9.4K
|
Manufacturing
|
37.02%
|
O:
1.71%
H:
1.28%
C:
0.94%
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-14.23%
|
O:
0.28%
H:
0.18%
C:
0.0%
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-7.13%
|
O:
0.07%
H:
0.42%
C:
0.07%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
-10.28%
|
O:
0.09%
H:
0.39%
C:
-0.36%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-7.04%
|
O:
1.47%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
6.49%
|
O:
0.76%
H:
4.31%
C:
2.11%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-2.03%
|
O:
-0.14%
H:
0.35%
C:
-1.12%
ABBV
|
$164.25
1.05%
-0.76%
4M
|
Health Technology
|
-3.96%
|
O:
1.48%
H:
0.0%
C:
0.0%
VRTX
|
$393.1
-0.27%
-0.27%
880K
|
Health Technology
|
-5.53%
|
O:
0.15%
H:
2.4%
C:
0.56%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-0.9%
|
O:
1.33%
H:
0.0%
C:
0.0%
JAZZ
|
News
|
$107.15
-1.61%
-1.63%
590K
|
Health Technology
|
-14.12%
|
O:
-0.02%
H:
0.0%
C:
-1.4%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
1.83%
|
O:
-0.4%
H:
0.19%
C:
-0.33%
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
-15.55%
|
O:
-0.18%
H:
0.0%
C:
-6.22%
report
cancer
blood
growth
market
Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU
Published:
2024-01-24
(Crawled : 14:30)
- biospace.com/
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-9.61%
|
O:
-0.32%
H:
0.0%
C:
0.0%
asco
bladder
cancer
treatment
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
Published:
2024-01-23
(Crawled : 11:01)
- prnewswire.com
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-10.61%
|
O:
-1.11%
H:
0.0%
C:
0.0%
million
cancer
series
therapeutics
FDA Decisions: J&J's Bladder Cancer Drug Wins Full Approval
Published:
2024-01-22
(Crawled : 14:30)
- biospace.com/
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-8.68%
|
O:
1.71%
H:
0.0%
C:
-0.15%
PRGO
|
$30.04
0.27%
0.0%
780K
|
Health Technology
|
-9.22%
|
O:
0.36%
H:
2.11%
C:
1.29%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-10.08%
|
O:
0.6%
H:
0.0%
C:
0.0%
ABT
|
News
|
$105.9
-3.03%
0.07%
12M
|
Health Technology
|
-5.27%
|
O:
0.88%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-10.01%
|
O:
-0.21%
H:
0.0%
C:
0.0%
fda
drug
approval
bladder
cancer
J&J Secures Full FDA Approval for Bladder Cancer Drug Balversa
Published:
2024-01-22
(Crawled : 13:30)
- biospace.com/
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-10.08%
|
O:
0.6%
H:
0.0%
C:
0.0%
fda
drug
approval
bladder
cancer
balversa
U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations
Published:
2024-01-19
(Crawled : 21:00)
- prnewswire.com
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
Email alert
Add to watchlist
balversa
drug
genetic
approval
food
bladder
cancer
treat
grants
advanced
FDA Decisions: Merck's Keytruda Wins 39th Overall Approval, Third in Cervical Cancer
Published:
2024-01-15
(Crawled : 17:00)
- biospace.com/
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
Email alert
Add to watchlist
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
Email alert
Add to watchlist
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
Email alert
Add to watchlist
PRGO
|
$30.04
0.27%
0.0%
780K
|
Health Technology
|
Email alert
Add to watchlist
ABT
|
News
|
$105.9
-3.03%
0.07%
12M
|
Health Technology
|
Email alert
Add to watchlist
fda
cancer
keytruda
Johnson & Johnson Submits Supplemental Biologics License Application and New Drug Application to U.S. FDA Seeking Approval of RYBREVANT® (amivantamab-vmjw) Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
Published:
2023-12-21
(Crawled : 13:00)
- prnewswire.com
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-7.46%
|
O:
-1.87%
H:
0.0%
C:
0.0%
rybrevant
fda
lung
drug
license
approval
cancer
cell
treatment
application
plus
Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight
Published:
2023-12-20
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-3.34%
|
O:
-0.1%
H:
0.0%
C:
0.0%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-7.46%
|
O:
-1.87%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
31.67%
|
O:
0.21%
H:
0.63%
C:
0.1%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-5.45%
|
O:
-0.08%
H:
0.0%
C:
0.0%
cancer
growth
study
market
← Previous
1
2
3
4
5
6
7
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.